Randomized clinical trial of laparoscopic versus open pancreatoduodenectomy for periampullary tumours. BJS 2017; 104: 1443-1450.
Published: 12th September 2017
Authors: C. Palanivelu, P. Senthilnathan, S. C. Sabnis, N. S. Babu, S. Srivatsan Gurumurthy, N. Anand Vijai et al.
Laparoscopic resection as an alternative to open pancreatoduodenectomy may yield short‐term benefits, but has not been investigated in a randomized trial. The aim of this study was to compare laparoscopic and open pancreatoduodenectomy for short‐term outcomes in a randomized trial.
Patients with periampullary cancers were randomized to either laparoscopic or open pancreatoduodenectomy. The outcomes evaluated were hospital stay (primary outcome), and blood loss, radicality of surgery, duration of operation and complication rate (secondary outcomes).
Of 268 patients, 64 who met the eligibility criteria were randomized, 32 to each group. The median duration of postoperative hospital stay was longer for open pancreaticoduodenectomy than for laparoscopy (13 (range 6–30)
Laparoscopy offered a shorter hospital stay than open pancreatoduodenectomy in this randomized trial. Registration number: NCT02081131(
You may also be interested in
Authors: M. Gelli, M. A. Allard, O. Farges, C. Paugam‐Burtz, J. Y. Mabrut, J. M. Regimbeau et al.
Notes: No increased risk
Meta‐analysis of delayed gastric emptying after pylorus‐preserving versus pylorus‐resecting pancreatoduodenectomy.
Authors: U. Klaiber, P. Probst, O. Strobel, C. W. Michalski, C. Dörr‐Harim, M. K. Diener et al.
Notes: No difference
Meta‐analysis of mortality in patients with high‐risk intraductal papillary mucinous neoplasms under observation.
Authors: G. Vanella, S. Crippa, L. Archibugi, P. G. Arcidiacono, G. Delle Fave, M. Falconi et al.
Notes: Low disease‐related mortality
Authors: P. Studer, T. Horn, A. Haynes, D. Candinas, V. M. Banz
Randomized clinical trial
Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer. BJS 2018; 105: 192-202.
Authors: T. Ebata, S. Hirano, M. Konishi, K. Uesaka, Y. Tsuchiya, M. Ohtsuka et al.
Notes: No advantage
Defining the molecular pathology of pancreatic body and tail adenocarcinoma. BJS 2018; 105: e183-e191.
Authors: S. B. Dreyer, N. B. Jamieson, R. Upstill‐Goddard, P. J. Bailey, C. J. McKay, A. V. Biankin et al.
Notes: Worse genetic profile in tail
Circulating tumour cells and DNA as liquid biopsies in gastrointestinal cancer. BJS 2018; 105: e110-e120.
Authors: O. Nordgård, K. Tjensvoll, B. Gilje, K. Søreide
Notes: The inner space frontier
Authors: M. A. Stammes, S. L. Bugby, T. Porta, K. Pierzchalski, T. Devling, C. Otto et al.
Notes: Visible results
Randomized clinical trial
Randomized clinical trial of duct‐to‐mucosa versus invagination pancreaticojejunostomy after pancreatoduodenectomy. BJS 2018; 105: 48-57.
Authors: Y. Senda, Y. Shimizu, S. Natsume, S. Ito, K. Komori, T. Abe et al.
Notes: No difference found
Early versus late recurrence of intrahepatic cholangiocarcinoma after resection with curative intent.
Authors: X.‐F. Zhang, E. W. Beal, F. Bagante, J. Chakedis, M. Weiss, I. Popescu et al.
Notes: Early recurrence is bad news
Growth rates of pulmonary metastases after liver transplantation for unresectable colorectal liver metastases. BJS 2018; 105: 295-301.
Authors: H. Grut, S. Solberg, T. Seierstad, M. E. Revheim, T. S. Egge, S. G. Larsen et al.
Notes: Immunosuppression may not accelerate growth